T Le1, L Hopkins, M Fung Kee Fung. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa General Hospital, 501 Smyth Road, Room 8130, Ottawa, Ontario, Canada. tle@ottawahospital.on.ca
Abstract
OBJECTIVES: This report assessed the quality of life of ovarian cancer patients undergoing adjuvant and salvage chemotherapy treatment. METHODS: All epithelial ovarian cancer patients requiring chemotherapy to manage their disease were recruited from university based gynecologic oncology clinics. Quality of life was measured using the FACT-O (Functional Assessment of Cancer Therapy-Ovarian module version 4) questionnaire. Descriptive statistics and two-way analysis of variance were used to compare the effect on the mean quality of life scores with respect to the indications of chemotherapy and best radiologic response. Any P value of less than 0.10 was considered worthy of interest. RESULTS: Ninety-three patients participated. In the adjuvant setting, there was a trend towards better quality of life with better response to therapy. In patients with a first recurrence, complete response to therapy clearly had a beneficial effect on overall quality of life compared to stable or partial response. There was no significant quality of life difference between those with partial response versus stable disease in a first recurrent setting. In patients with more than one recurrence, no large change in overall quality of life was observed across the range of tumor responses. CONCLUSION: Chemotherapy is beneficial to improve quality of life of ovarian cancer patients. Differential effect of tumor response status on quality of life at different treatment phases requires further investigations.
OBJECTIVES: This report assessed the quality of life of ovarian cancerpatients undergoing adjuvant and salvage chemotherapy treatment. METHODS: All epithelial ovarian cancerpatients requiring chemotherapy to manage their disease were recruited from university based gynecologic oncology clinics. Quality of life was measured using the FACT-O (Functional Assessment of Cancer Therapy-Ovarian module version 4) questionnaire. Descriptive statistics and two-way analysis of variance were used to compare the effect on the mean quality of life scores with respect to the indications of chemotherapy and best radiologic response. Any P value of less than 0.10 was considered worthy of interest. RESULTS: Ninety-three patients participated. In the adjuvant setting, there was a trend towards better quality of life with better response to therapy. In patients with a first recurrence, complete response to therapy clearly had a beneficial effect on overall quality of life compared to stable or partial response. There was no significant quality of life difference between those with partial response versus stable disease in a first recurrent setting. In patients with more than one recurrence, no large change in overall quality of life was observed across the range of tumor responses. CONCLUSION: Chemotherapy is beneficial to improve quality of life of ovarian cancerpatients. Differential effect of tumor response status on quality of life at different treatment phases requires further investigations.
Authors: Mi Hyang Um; Mi Youn Choi; Song Mi Lee; Ik Jae Lee; Chang Geol Lee; Yoo Kyoung Park Journal: Support Care Cancer Date: 2014-06-07 Impact factor: 3.603
Authors: Abdel W Awadalla; Jude U Ohaeri; Abdullah Gholoum; Ahmed O A Khalid; Hussein M A Hamad; Anila Jacob Journal: BMC Cancer Date: 2007-06-19 Impact factor: 4.430